Suppr超能文献

卵巢透明细胞癌错配修复状态的临床病理及生存特征。

Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.

机构信息

Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

J Surg Oncol. 2020 Sep;122(3):538-546. doi: 10.1002/jso.25965. Epub 2020 May 12.

Abstract

BACKGROUND AND OBJECTIVES

We sought to explore the expression of mismatch repair (MMR) status and its correlation with clinicopathologic and survival characteristics in ovarian clear cell carcinoma (OCCC).

METHODS

Expression of four MMR proteins (MLH1, PMS, MSH2, and MSH6) were measured using tissue microarray-based immunohistochemistry in 120 OCCC patients. The associations of clinicopathologic parameters with recurrence-free survival (RFS) and overall survival (OS) were analyzed by the Kaplan-Meier method, and multivariate analysis was further performed by the Cox regression model.

RESULTS

Overall, 120 OCCC patients met the entry criteria, and their MMR status was detected, consisting of 24 patients with dMMR and 96 patients with proficient MMR (pMMR). Patients with dMMR were strongly associated with platinum-sensitive disease (P = .006) and large tumor volume (P = .038). Among all the patients who have received surgery, tumors with dMMR had a better RFS and OS than those with pMMR (hazard ratio [HR] for recurrence: 0.459 [95% confidence interval {95% CI} = 0.224-0.940], P = .029; HR for death: 0.381 [95% CI = 0.170-0.853], P = .015). In subgroup analysis, dMMR patients experienced a better trend of RFS (HR = 0.273; P = .055) and OS (HR = 0.165; P = .040) than pMMR cases among early stages (I-II), but this difference was not observed in advanced stage (III-IV) patients. Meanwhile, pMMR was associated with a more favorable trend of prognosis than dMMR in platinum-resistant patients (RFS: HR = 0.317, P = .051; OS: HR = 0.370, P = .046). Multivariate analysis revealed that only advanced stages (III-IV) were adverse independent prognosticators for both RFS (HR = 5.938 [95% CI = 2.804-12.574]; P < .001) and OS (HR = 6.209 [95% CI = 2.724-14.156]; P < .001).

CONCLUSION

Tumors with dMMR were related to better OS in OCCC on univariate analysis. Only the tumor stage was an independent prognosticator for both RFS and OS. MMR status is a potentially valuable prognostic index in OCCC patients, and larger prospective studies are required to validate its prognostic role.

摘要

背景与目的

本研究旨在探讨卵巢透明细胞癌(OCCC)中错配修复(MMR)状态的表达及其与临床病理和生存特征的相关性。

方法

采用组织微阵列免疫组织化学法检测 120 例 OCCC 患者中 4 种 MMR 蛋白(MLH1、PMS、MSH2 和 MSH6)的表达。采用 Kaplan-Meier 法分析临床病理参数与无复发生存(RFS)和总生存(OS)的关系,采用 Cox 回归模型进行多因素分析。

结果

共纳入 120 例符合入组标准的 OCCC 患者,检测其 MMR 状态,其中 dMMR 患者 24 例,pMMR 患者 96 例。dMMR 患者与铂类敏感疾病(P = .006)和较大肿瘤体积(P = .038)密切相关。在所有接受手术的患者中,dMMR 肿瘤的 RFS 和 OS 均优于 pMMR 肿瘤(复发风险比 [HR]:0.459 [95%置信区间 {95%CI} = 0.224-0.940],P = .029;死亡风险比 [HR]:0.381 [95%CI = 0.170-0.853],P = .015)。亚组分析显示,dMMR 患者在早期(I-II 期)的 RFS(HR = 0.273;P = .055)和 OS(HR = 0.165;P = .040)方面的预后趋势优于 pMMR 病例,但在晚期(III-IV 期)患者中未观察到这种差异。同时,pMMR 与铂类耐药患者更有利的预后趋势相关(RFS:HR = 0.317,P = .051;OS:HR = 0.370,P = .046)。多因素分析显示,仅晚期(III-IV 期)是 RFS(HR = 5.938 [95%CI = 2.804-12.574];P < .001)和 OS(HR = 6.209 [95%CI = 2.724-14.156];P < .001)的独立预后不良因素。

结论

在单因素分析中,dMMR 肿瘤与 OCCC 的 OS 相关。只有肿瘤分期是 RFS 和 OS 的独立预后因素。MMR 状态是 OCCC 患者有价值的预后指标,需要更大规模的前瞻性研究来验证其预后作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验